This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
by Zacks Equity Research
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Why Kamada (KMDA) Could Beat Earnings Estimates Again
by Zacks Equity Research
Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kamada (KMDA) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services
by Zacks Equity Research
Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services
Look Beyond Earnings: 4 Stocks With Increasing Cash Flows
by Moumita C. Chattopadhyay
Cash is an indispensable factor for any company. It gives strength and vitality to a company and is the key to its existence, development and success.
Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX
by Zacks Equity Research
Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX
Tap These 6 Stocks That Flaunt Impressive Net Profit Margin
by Zacks Equity Research
Let's consider six stocks with a remarkable net profit margin to build a successful portfolio.
New Strong Buy Stocks for July 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
Kamada (KMDA) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.
Kamada (KMDA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.
Kamada (KMDA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day.
Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (KMDA) Outperforming Other Medical Stocks This Year?
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
5 Stocks With Increasing Cash Flows to Scoop Up Big Gains
by Moumita Chattopadhyay
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
Acorda to Gain From Inbrija Sales and Neurological Pipeline
by Zacks Equity Research
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
by Zacks Equity Research
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Kamada (KMDA) closed at $5.95, marking a -1.16% move from the previous day.
Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin
by Zacks Equity Research
Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.